Table 2.

Early Clinical Studies of VEGF Blockade in Malignant and Non-malignant Effusions

Patients (n)	Antiangiogenic Treatment	Outcome
NMPE (1) [150]	Bev 5 mg/kgA	Reduced in 1/1
NMPE (1) [154]	Bev 5 mg/kgB	Resolved in 1/1
MPE (2) [151]	Bev 5 mg/kgC	Not Resolved in 2/2
MPE (13) [152]	Bev 15 mg/kgB	Controlled in 12/13 (92.3%)
MA (4) [11]	Bev 15 mg/kgB	Controlled in 4/4
MA (2) [151]	Bev 15 mg/kgA	Resolved or Reduced in 2/2
MA (1) [155]	Bev 15 mg/kgB	Resolved in 1/1
MA (1) [156]	IP Bev 5 mg/kgD	Reduced in 1/1
MA (9) [157]	IP Bev 5 mg/kgD	Resolved in 9//9

Bev: Bevacizumab; IP: intraperitoneal; MA: malignant ascites; MPE: malignant pleural effusion; NMPE: nonmalignant pleural effusion. Treatment schedule as follows:

^Aonce;

^Bevery three weeks;

^C5 mg/kg initial dose was followed by one more dose of 5 mg/kg in one patient and 10 mg/kg in the other;

^Dmonthly.